Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Golidocitinib, and Selinexor for R/R NKTCL
NCT06966154Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib and selinexor in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Fudan University. Primary endpoints: Recommended Phase II Dose of golidocitinib in combination with selinexor at 4 weeks, Safety profile at 6 months and 1 more. Started May 2025; status: recruiting.
02
Drugs
golidocitinibselinexor
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06966154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966154.